Nothing generic about Mayne Pharma

Wilson Asset Management

Wilson Asset Management

On Tuesday, Mayne Pharma Group Limited (ASX: MYX) announced it had agreed to pay US$652 million ($887 million) for 42 generic drugs from Teva Pharmaceutical Industries and Allergan. The company said the acquired portfolio is expect to contribute sales of US$237 million in FY 2017 and will “propel Mayne Pharma into the top 25 retail generic pharmaceutical companies in the United States”. Shares in Mayne Pharma soared following the announcement, and closed up 31.6% for the week. We own Mayne Pharma as a ‘research driven’ investment for WAM Capital and WAM Research.


MORE ON



1 stock mentioned

Wilson Asset Management has a track record of making a difference for shareholders and the community for more than 20 years. As the investment manager for eight leading LICs – WAM Capital (ASX: WAM), WAM Leaders (ASX: WLE), WAM Global (ASX: WGB),...

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.